|
1
|
Yatabe Y, Borczuk AC and Powell CA: Do all
lung adenocarcinomas follow a stepwise progression? Lung Cancer.
74:7–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kadara H, Kabbout M and Wistuba II:
Pulmonary adenocarcinoma: a renewed entity in 2011. Respirology.
17:50–65. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu L, Deng HX, Xia JH, Yang Y, Fan CH,
Hung WY and Siddque T: Assignment of SATB1 to human chromosome band
3p23 by in situ hybridization. Cytogenet Cell Genet. 77:205–206.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Beyer M, Thabet Y, Müller RU, Sadlon T,
Classen S, Lahl K, Basu S, Zhou X, Bailey-Bucktrout SL, Krebs W, et
al: Repression of the genome organizer SATB1 in regulatory T cells
is required for suppressive function and inhibition of effector
differentiation. Nat Immunol. 12:898–907. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Han HJ, Russo J, Kohwi Y and
Kohwi-Shigematsu T: SATB1 reprogrammes gene expression to promote
breast tumour growth and metastasis. Nature. 452:187–193. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Tian X, Ji H, Guan X, Xu W, Dong
B, Zhao M, Wei M, Ye C, Sun Y, et al: Expression of SATB1 promotes
the growth and metastasis of colorectal cancer. PLoS One.
9:e1004132014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Han B, Luan L, Xu Z and Wu B: Expression
and biological roles of SATB1 in human bladder cancer. Tumour Biol.
34:2943–2949. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shukla S, Sharma H, Abbas A, MacLennan GT,
Fu P, Danielpour D and Gupta S: Upregulation of SATB1 is associated
with prostate cancer aggressiveness and disease progression. PLoS
One. 8:e535272013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zuk K, Peczek L, Stec-Michalska K, Medrek
M and Nawrot B: SATB1 expression in gastric mucosa in relation to
Helicobacter pylori infection and family history of gastric cancer.
Adv Med Sci. 57:237–243. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Groome PA, Bolejack V, Crowley JJ, Kennedy
C, Krasnik M, Sobin LH and Goldstraw P: IASLC International Staging
Committee; Cancer Research and Biostatistics; Observers to the
Committee; Participating Institutions: The IASLC Lung Cancer
Staging Project: Validation of the proposals for revision of the T,
N, and M descriptors and consequent stage groupings in the
forthcoming (seventh) edition of the TNM classification of
malignant tumours. J Thorac Oncol. 2:694–705. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Notsuda H, Sakurada A, Endo C, Okada Y,
Horii A, Shima H and Kondo T: p190A RhoGAP is involved in EGFR
pathways and promotes proliferation, invasion and migration in lung
adenocarcinoma cells. Int J Oncol. 43:1569–1577. 2013.PubMed/NCBI
|
|
12
|
Keaney J, Campbell M and Humphries P: From
RNA interference technology to effective therapy: how far have we
come and how far to go? Ther Deliv. 2:1395–1406. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xia L, Guan W, Wang D, Zhang YS, Zeng LL,
Li ZP, Wang G and Yang ZZ: Killing effect of Ad5/F35-APE1 siRNA
recombinant adenovirus in combination with hematoporphrphyrin
derivative-mediated photodynamic therapy on human nonsmall cell
lung cancer. Biomed Res Int. 2013:9579132013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yi X, Zhao G, Zhang H, Guan D, Meng R,
Zhang Y, Yang Q, Jia H, Dou K, Liu C, et al: MITF-siRNA formulation
is a safe and effective therapy for human melasma. Mol Ther.
19:362–371. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hanker LC, Karn T, Mavrova-Risteska L,
Ruckhäberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A and
Wiegratz I: SATB1 gene expression and breast cancer prognosis.
Breast. 20:309–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Selinger CI, Cooper WA, Al-Sohaily S,
Mladenova DN, Pangon L, Kennedy CW, McCaughan BC, Stirzaker C and
Kohonen-Corish MR: Loss of special AT-rich binding protein 1
expression is a marker of poor survival in lung cancer. J Thorac
Oncol. 6:1179–1189. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang B, Zhou H, Wang X and Liu Z:
Silencing SATB1 with siRNA inhibits the proliferation and invasion
of small cell lung cancer cells. Cancer Cell Int. 13:82013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bankert RB, Balu-Iyer SV, Odunsi K, Shultz
LD, Kelleher RJ Jr, Barnas JL, Simpson-Abelson M, Parsons R and
Yokota SJ: Humanized mouse model of ovarian cancer recapitulates
patient solid tumor progression, ascites formation, and metastasis.
PLoS One. 6:e244202011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang XF, Hou ZB, Dai XZ, Chen C, Ge J,
Shen H, Li XF, Yu LK and Yuan Y: Special AT-rich sequence-binding
protein 1 promotes cell growth and metastasis in colorectal cancer.
World J Gastroenterol. 19:2331–2339. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cai S, Han HJ and Kohwi-Shigematsu T:
Tissue-specific nuclear architecture and gene expression regulated
by SATB1. Nat Genet. 34:42–51. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mir R, Pradhan SJ and Galande S: Chromatin
organizer SATB1 as a novel molecular target for cancer therapy.
Curr Drug Targets. 13:1603–1615. 2012. View Article : Google Scholar : PubMed/NCBI
|
